secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2023-02-07T23:59:59+00:00
Accession:  0001213900-23-008965
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive receives Nasdaq delisting notice for bid price non-compliance; equity below $5M
--------------------------------------------------------------------------------

- On Feb 1, 2023, Nasdaq notified Unicycive (UNCY) that it failed to regain minimum bid price compliance by Jan 30 deadline.
- Company not eligible for second 180-day grace period because stockholders' equity of $4.626M was below $5M initial listing requirement.
- Unicycive requested a hearing before the Nasdaq Hearings Panel, scheduled for March 23, 2023, to stay delisting.
- If Panel grants extension, company may have until August 8, 2023 to cure bid-price deficiency.
- Common stock continues trading on Nasdaq under symbol UNCY pending hearing outcome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/0001213900-23-008965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390023008965/ea172745-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-008965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer